Potential contribution of 131I-Labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: Pretherapeutic study with dose recovery in resected tissues

20 patients with liver metastases from colorectal carcinoma undergoing laparotomy received 15–60 mg intravenously, either intact or fragments of, anti-carcinoembryonic antigen (anti-CEA) monoclonal antobodies labelled with 0.55–1.48 GBq (15–40 mCi) of 131I, 3–8 days prior to operation. The uptake measured per gram of metastases ranged from 0.33 to 6.6 × 10 −3% of injected dose. Tumour to liver uptake ratios ranged from 2 to 33. The radiation dose, estimated in 6 patients (3 of each group), for an extrapolated dose of 3.7 GBq (100 mCi) of 131I ranged from 0.3 to 0.8 Gy in normal liver or spleen (an acceptable estimate for bone marrow radiation dose) and from 3.4 to 8.2 Gy to the hepatic metastases, indicating that probably other therapeutic modalities should be associated with radioimmunotherapy.